Get the Stockscreener App
9.54
0.10%
-0.01
After Hours:
9.59
0.05
+0.52%
Vir Biotechnology Inc stock is traded at $9.54, with a volume of 3.09M.
It is down -0.10% in the last 24 hours and down -5.36% over the past month.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
See More
Previous Close:
$9.55
Open:
$9.51
24h Volume:
3.09M
Relative Volume:
1.17
Market Cap:
$1.61B
Revenue:
$68.56M
Net Income/Loss:
$-437.99M
P/E Ratio:
-3.0153
EPS:
-3.1639
Net Cash Flow:
$-396.61M
1W Performance:
+3.81%
1M Performance:
-5.36%
6M Performance:
+48.60%
1Y Performance:
+83.82%
1-Day Range:
$9.47
$9.91
1-Week Range:
$8.86
$9.91
52-Week Range:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.54 | 1.61B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Vir Biotechnology (VIR) director receives RSU and stock option grants - Stock Titan
Vir Biotechnology (VIR) director granted 8,000 RSUs and 16,000 options - Stock Titan
Vir Biotechnology (VIR) director granted RSUs and 16,000-share stock option - Stock Titan
Vir Biotechnology (VIR) director receives 8,000 RSUs and 16,000 stock options - Stock Titan
Vir Biotechnology (VIR) director awarded 8,000 RSUs and 16,000-share stock option - Stock Titan
Vir Biotechnology (VIR) director granted RSUs and 16,000-share option - Stock Titan
Vir Biotechnology, Inc. 8-K Filing Details for May 25, 2026: Company Information, NASDAQ Listing, and Executive Certification - Minichart
Vir Biotechnology, Inc. Announces Changes in Board and Audit Committee, Effective May 26, 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR) - The Globe and Mail
Vir Biotechnology (Nasdaq: VIR) reports director exit and 2026 vote outcomes - Stock Titan
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - AOL.com
UBS Group AG Purchases 203,203 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Gilead wins hepatitis D drug approval as two Bay Area rivals line up their drugs - The Business Journals
How Marianne De Backer saved Vir after flu drug failure - The Business Journals
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million - AOL.com
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares - AOL.com
How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story - Yahoo Finance
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - The Motley Fool
Vir Biotechnology’s SWOT analysis: stock gains momentum on partnership and clinical progress - Investing.com UK
Earnings call transcript: Vir Biotech’s Q1 2026 sees wider losses, stock dips - Investing.com Nigeria
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver Congress 2026 - marketscreener.com
VIR: Vir Biotechnology Prepares to Present Trial Data at EASL Co - GuruFocus
Vir Biotechnology to present hepatitis delta trial data at EASL By Investing.com - Investing.com South Africa
Vir Biotechnology to present hepatitis delta trial data at EASL - Investing.com UK
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial - TipRanks
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 - Business Wire
Boxer Capital Management Boosts Vir Biotechnology Holdings in Q1 2026 FilingNews and Statistics - IndexBox
User | bigspringherald.comVir Biotechnology, Inc.Common Stock (Nasdaq:VIR) Stock Quote - FinancialContent
Vir Biotechnology, Inc.Common Stock (NQ: VIR - FinancialContent
Vir Biotechnology rated buy on strong cash, late-stage drugs, and key partnerships through 2028 - Pluang
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity (NASDAQ:VIR) - Seeking Alpha
SoftBank group reports 10.95M-share stake in Vir Biotechnology (VIR) - Stock Titan
Vanguard Group Inc. Reduces Stock Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):